Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

Prognostic value of plasma brain-derived pTau.

Valentina Ghisays¹, Marisa N Denkinger², Alpana Singh²

¹Banner Alzheimer's Institute, Phoenix, AZ, USA.

Medrxiv : the Preprint Server for Health Sciences

|July 10, 2026

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy.

JAMA network open·2026

Same author

A plasma protein signature for cerebral amyloid angiopathy.

Acta neuropathologica·2026

Same author

Associations of plasma biomarkers with age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred.

The journal of prevention of Alzheimer's disease·2026

Same author

Stress-induced glucocorticoid signaling impairs enteric neurotrophin BDNF-TrkB pathway and drives gastrointestinal dysmotility.

The Journal of biological chemistry·2026

Same author

GPND-AI NULISA: A 15-Protein AI classifier for diagnosis and co-pathology profiling across neurodegenerative diseases.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

TAS2R38 taster variants-linked MGAM expression in Alzheimer's disease: a novel target for precision drug repurposing.

Frontiers in aging neuroscience·2026

Plasma brain-derived pTau217 (BD-pTau217) shows promise for predicting Alzheimer's disease progression. BD-pTau217 better predicts amyloid PET positivity in early stages than total pTau217.

Area of Science:

Neurodegenerative diseases
Biomarker discovery
Alzheimer's disease research

Background:

Plasma biomarkers are crucial for Alzheimer's disease (AD) diagnosis and prognosis.
Brain-derived pTau217 (BD-pTau217) may offer greater AD specificity than total pTau217.
The prognostic value of BD-pTau217 for predicting clinical and amyloid progression remains unclear.

Purpose of the Study:

To compare the prognostic value of BD-pTau217 versus total plasma pTau217.
To assess their ability to predict clinical and amyloid PET progression in cognitively unimpaired (CU) individuals.
To evaluate biomarker performance in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.

Main Methods:

Utilized plasma biomarker data from 1,427 ADNI participants, including 529 CU individuals.

Keywords:

Alzheimer’s disease progression Brain-derived pTau217 amyloid PET progression plasma biomarkers plasma phosphorylated tau

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Related Experiment Videos

Last Updated: Jul 12, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Assessed amyloid PET progression in baseline CU amyloid-negative participants using longitudinal PET imaging.

Employed Cox models and time-dependent AUC to evaluate associations between biomarkers and progression.

Main Results:

BD-pTau217 did not significantly outperform total pTau217 in predicting progression to mild cognitive impairment or dementia.
However, BD-pTau217 demonstrated superior prediction of amyloid PET positivity at 2.5 and 4 years in amyloid-negative participants (tdAUC 0.82 vs 0.69 and 0.77 vs 0.64, respectively).
Hazard ratios indicated a significantly higher risk of progression with elevated BD-pTau217.

Conclusions:

BD-pTau217 enhances the prediction of near-term amyloid PET progression in cognitively unimpaired individuals.
The advantage of BD-pTau217 for predicting clinical progression is less pronounced.
Plasma BD-pTau217 shows potential as a sensitive biomarker for early AD-related changes.